PNC-27 (10mg)

Name: PNC-27 (10mg)
SKU: 571
Availability: InStock

$140.00

PNC-27 is a membrane-active peptide for in vitro anticancer research applications that selectively kills cancer cells by binding to HDM-2 on their membranes and inducing necrosis through pore formation.

Category: Vials

Description
Reviews (0)

PNC-27 Product Description

PNC-27 is a synthetic peptide designed to selectively kill cancer cells by targeting a protein called HDM-2 (also known as MDM2) found on the membranes of many cancer cells. It works by binding to membrane-bound HDM-2, forming pores in the cancer cell membrane, and causing rapid cell death through necrosis, while sparing normal cells.

PNC-27 is derived from the p53 protein’s HDM-2 binding domain (amino acids 12-26) and is linked to a membrane-penetrating sequence, allowing it to enter and act on cancer cell membranes. The peptide binds specifically to HDM-2 present on the surface of cancer cells, not normal cells. This binding leads to the formation of transmembrane pores, disrupting the cell membrane and causing cell lysis and necrosis, independent of the p53 pathway.

Peptide Information

Property	Value
Peptide Sequence	Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly
Molecular Formula	C188H293N53O44S
Molecular Weight	4029.2 g/mol
CAS Number	1159861-00-3
Synonyms	H-PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG-OH, PPLSQETFSDLWKLLKKWKMRRNQFWVKVQRG-acid, H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH, A6, Paralit

PNC-27 Peptide Structure

32 Amino acid peptide.png

Source: PubChem

Lyophilized Peptides:

These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process.

Product Usage:

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug.

PNC-27 Research

PNC-27 research has focused on its mechanism of action, selectivity for cancer cells, and potential as a broad-spectrum anti-cancer agent, including its effects on primary tumors and chemoresistant cancers.

Membrane Pore Formation

PNC-27 contains a segment from the p53 protein that binds to HDM-2 on cancer cell membranes. This binding leads to the formation of transmembrane pores, causing rapid necrosis of cancer cells by allowing cell contents to leak out.[1] The peptide forms 1:1 complexes with HDM-2, which then dimerize to create these pores.[1]

Selectivity for Cancer Cells

PNC-27 targets cancer cells because they express high levels of membrane-bound HDM-2, unlike normal cells, which have little or none. This selectivity results in minimal toxicity to normal cells, including hematopoietic stem cells and other non-cancerous tissues.[1]

Broad Anticancer Activity

PNC-27 has demonstrated cytotoxicity against a wide range of solid and hematopoietic tumors, including chemotherapy-resistant cancers and primary tumor cells from ovarian and uterine cancers. The anticancer peptide has also shown efficacy in animal models, eradicating metastatic pancreatic tumors and leukemia stem cells. [1][2][3]

Primary Tumor Studies

Ex vivo studies on freshly isolated primary human ovarian and uterine cancer cells confirmed that PNC-27 induces dose-dependent cell death, with no observed effect on normal cells.[2]